The Albumin Challenge for Hepatorenal Syndrome

The albumin challenge is a bedside test and an early treatment rolled into one: a patient with advanced liver disease and a sudden rise in creatinine receives intravenous albumin to expand blood volume, and clinicians watch whether kidney function improves. If creatinine keeps climbing after adequate volume resuscitation, the working diagnosis shifts toward hepatorenal syndrome–acute kidney injury (HRS-AKI), a condition driven not by structural kidney damage but by the profound circulatory collapse that accompanies decompensated cirrhosis. The logic is straightforward, but the clinical reality is anything but. How much albumin to give, how long to wait, and what to do when the kidneys do not respond are questions that remain actively debated even in the latest consensus guidelines.

Why the Kidneys Fail in Advanced Liver Disease

In cirrhosis with portal hypertension, blood vessels in the gut dilate excessively. That splanchnic vasodilation pulls blood away from the central circulation, leaving the kidneys effectively underfilled even when the patient’s total body fluid is normal or even high. The body compensates by ramping up the renin-angiotensin-aldosterone system and releasing antidiuretic hormone, which retains sodium and water but cannot fully restore kidney perfusion. Over time, the glomerular filtration rate drops.

This circulatory dysfunction is the core mechanism behind HRS-AKI. The kidneys themselves are structurally intact; they are simply starved of blood flow. That distinction is what makes the albumin challenge meaningful: if the kidneys perk up when you push fluid into the vascular space, the problem was straightforward volume depletion (prerenal azotemia). If they do not, you are likely dealing with HRS-AKI or, less commonly, actual structural kidney damage such as acute tubular necrosis.¹ The hyperdynamic circulatory state that drives this process also contributes to cirrhotic cardiomyopathy and autonomic dysfunction, meaning the heart and nervous system are both compromised alongside the kidneys.²

How the Albumin Challenge Works in Practice

Current diagnostic criteria for HRS-AKI require cirrhosis with ascites, a rise in serum creatinine of at least 0.3 mg/dL within 48 hours or at least 50% from a recent baseline, and no improvement in creatinine or urine output within 24 hours after adequate volume resuscitation. There also has to be no strong evidence pointing to a different cause of the kidney injury.³ The albumin infusion step is what “adequate volume resuscitation” typically means in this population. The standard approach has been to give 1 gram of albumin per kilogram of body weight (up to 100 grams) over one to two days and then reassess.

What makes this tricky is deciding how long to wait. Some guidelines have pushed for limiting albumin to a 24-hour window, reasoning that a shorter trial is enough to rule out simple dehydration and avoids fluid overload in patients who already have ascites and edema. But newer evidence has pushed back on this timeline, showing that a meaningful proportion of patients respond between 24 and 48 hours after albumin infusion, and restricting the window may cause clinicians to prematurely label patients as non-responders.⁴

Why Albumin Instead of Regular IV Fluids

Albumin is the most abundant protein in blood plasma and is responsible for roughly three-quarters of the osmotic pressure that keeps fluid inside blood vessels. In decompensated cirrhosis, serum albumin levels are often dangerously low because the failing liver can no longer produce enough. Infusing exogenous albumin pulls water from the tissue spaces back into the bloodstream, expanding the effective circulating volume more efficiently than crystalloid solutions like normal saline.⁵ That capacity for plasma expansion is the reason albumin has been the fluid of choice for volume challenges in this population for decades.⁶

Albumin also does more than just hold water in the vascular space. The molecule has antioxidant properties, binds and transports drugs, modulates immune responses, and stabilizes the lining of blood vessels.⁷ In decompensated cirrhosis, however, the albumin molecules already circulating in the blood are often structurally damaged by the body’s chronic inflammatory and oxidative state, which impairs these non-volume-expansion functions.⁸ Infusing fresh albumin temporarily shifts the balance, but one study found that while the redox state of circulating albumin changed briefly after infusion, the binding function of the overall albumin pool did not measurably improve in patients with chronic liver failure.⁹ The practical takeaway is that albumin’s volume-expanding effect is reliable, but its broader molecular benefits in this patient group may be less dramatic than once hoped.

The Crystalloid Controversy

A reasonable question for clinicians and patients alike is whether cheaper crystalloid solutions could substitute for albumin in the initial volume challenge. Recent consensus panels from the Acute Disease Quality Initiative and the International Club of Ascites recommended trying crystalloids first, reserving albumin for the formal diagnostic trial. The rationale was partly economic and partly about simplicity: crystalloids are universally available and do not carry risks associated with blood-derived products.

However, a large retrospective study comparing albumin and crystalloid resuscitation in cirrhosis patients with AKI found that albumin was not clearly superior in terms of kidney recovery or in-hospital survival after statistical adjustments.¹⁰ That result surprised many hepatologists, and the debate continues. The newer evidence referenced above, showing responses occurring beyond 24 hours with albumin, has led some experts to argue that the pendulum swung too far toward crystalloids and that albumin’s unique properties in cirrhosis justify its continued first-line use.⁴ This is one of the rare areas in medicine where the standard-of-care is genuinely in flux: two expert groups, both working from evidence, reach different conclusions about what fluid to start with.

When the Challenge Fails and Vasoconstrictors Enter the Picture

If the albumin challenge does not improve kidney function, the next step is adding a vasoconstrictor drug. The idea is to counteract the splanchnic vasodilation pharmacologically: constrict the dilated gut vessels, redirect blood back to the central circulation, and restore kidney perfusion. Albumin continues alongside the vasoconstrictor, so in practice the treatment is always a combination.

Terlipressin, a vasopressin analogue, has the strongest evidence base. In the pivotal CONFIRM trial, about a third of patients receiving terlipressin plus albumin achieved verified reversal of HRS, compared to roughly one in six on albumin plus placebo.¹¹ An older and smaller randomized trial found kidney function improvement in about 44% of patients on terlipressin plus albumin versus 9% on albumin alone.¹² And in an early non-randomized study, albumin co-administration was identified as the strongest predictor of a complete response to terlipressin, with a 77% response rate in patients who received both, compared to 25% in those getting terlipressin alone.¹³ Albumin, in other words, is not merely a diagnostic tool but a critical therapeutic partner for vasoconstrictor therapy.

In settings where terlipressin is unavailable or too expensive, norepinephrine (which requires an ICU setting and central venous access) or the oral combination of midodrine and octreotide serve as alternatives. One randomized trial found norepinephrine plus albumin significantly outperformed midodrine/octreotide plus albumin, with complete response rates of about 58% versus 20%.¹⁴ But other trials have not found such a dramatic gap. One study reported complete response rates of roughly 73% and 75% for norepinephrine and midodrine/octreotide, respectively, with no statistically significant difference.¹⁵ Another showed response rates of 28% versus 12% that also did not reach statistical significance.¹⁶ The inconsistency across these small trials is a genuine problem; the evidence is not yet strong enough to declare one alternative definitively better than another, though norepinephrine tends to be preferred when ICU access is available.

Telling HRS Apart From Structural Kidney Damage

The albumin challenge helps distinguish HRS from prerenal azotemia (simple dehydration), but distinguishing HRS from acute tubular necrosis (ATN), where the kidney tubules are actually injured, remains harder. Both conditions can look identical on standard blood tests after the albumin challenge fails. Kidney biopsy would be the gold standard, but it is almost never performed in patients with cirrhosis because of their high bleeding risk.

Urinary biomarkers have been studied as a workaround. Neutrophil gelatinase-associated lipocalin (NGAL) tends to be much higher in ATN than in HRS, and interleukin-18 follows a similar pattern. One study found that most kidney biomarkers could distinguish ATN from prerenal azotemia, but only NGAL, interleukin-18, urinary albumin, and fractional excretion of sodium could separate ATN from HRS. Fractional excretion of sodium was the only marker able to distinguish HRS from prerenal azotemia on its own.¹⁷

Initial excitement about NGAL has been tempered by practical limitations. Levels can rise during chronic inflammation, sepsis, and chronic kidney disease independently of ATN, and there is substantial overlap between diagnostic groups. Because liver cells also produce NGAL during infection, a cirrhosis patient with sepsis may have an elevated urinary NGAL that has nothing to do with tubular damage.¹⁸ Clinicians therefore rely on a combination of the albumin challenge, urine biomarkers, clinical context, and pattern recognition rather than any single test.

Guiding Albumin Doses With Bedside Ultrasound

One of the underappreciated risks of albumin infusion in cirrhosis patients is fluid overload. These patients already have excess total body water (that is what ascites is), so adding more volume to the bloodstream can tip the balance toward pulmonary edema or worsen third-spacing. A study using point-of-care ultrasound (POCUS) to monitor patients during albumin infusions found signs of potentially severe intravascular volume overload in about one in five patients with decompensated cirrhosis.¹⁹

POCUS allows clinicians to look at the inferior vena cava, jugular veins, lung tissue, and kidney blood flow in real time. By integrating these images, a clinician can gauge whether a patient can tolerate more albumin or needs a pause. The goal is to move away from one-size-fits-all albumin dosing toward an approach tailored to the individual’s hemodynamic state.²⁰ This is still emerging practice rather than established standard of care, but it addresses a real gap: most albumin protocols assume a level of fluid tolerance that not every cirrhosis patient actually has.

Long-Term Albumin for Preventing HRS in the First Place

The albumin challenge is an acute intervention, but there is a growing body of evidence around giving regular albumin infusions over months to patients with cirrhosis and ascites as a preventive strategy. The Italian ANSWER trial assigned patients with cirrhosis and uncomplicated ascites to standard medical therapy with or without weekly albumin infusions. Over 18 months, the albumin group had significantly better survival, with a 38% reduction in the risk of death. They also had roughly half the need for large-volume paracentesis, fewer infections, less hepatic encephalopathy, and fewer episodes of HRS.²¹ The incidence of complications across the board dropped by roughly 30–67%, and hospital days fell substantially.²²

A separate study in patients with refractory ascites confirmed the pattern: two-year mortality was about 42% in the albumin group versus 66% in the standard-of-care group, and the albumin-treated patients spent significantly less time in the hospital.²³ Long-term albumin is not universally adopted yet, partly because of cost and partly because not every healthcare system can support regular outpatient infusions, but it represents a shift in thinking: rather than waiting for HRS to develop and then scrambling to treat it, ongoing albumin therapy may keep patients out of the danger zone entirely.

Albumin for Spontaneous Bacterial Peritonitis

One of the most common triggers for HRS is spontaneous bacterial peritonitis (SBP), an infection of the ascitic fluid. A landmark trial found that giving albumin alongside antibiotics during SBP episodes reduced kidney impairment from 33% to 10% and improved survival.²⁴ This has become one of the best-established uses of albumin in hepatology and is recommended in essentially all guidelines.

Whether every SBP patient needs albumin or only those at higher risk has been debated. Available evidence suggests the benefit is clearest in patients with already elevated bilirubin, blood urea nitrogen, or creatinine, markers that indicate the kidneys and liver are already under significant stress.²⁵ In lower-risk patients, the benefit is less certain, and some clinicians opt for crystalloid expansion instead. The safest approach, given the stakes of missing kidney injury, remains albumin for SBP patients until more refined risk-stratification tools are available.

When Albumin and Vasoconstrictors Both Fail

Not every patient responds to the combination of albumin and vasoconstrictor therapy. For those who do not, the definitive treatment is liver transplantation. The kidney dysfunction in HRS is driven by liver failure, so replacing the liver resolves the circulatory problem and typically restores kidney function. Renal replacement therapy (dialysis) serves as a bridge to transplant rather than a long-term solution. Patients who have had prolonged AKI, underlying chronic kidney disease, or hereditary kidney conditions may need a combined liver-kidney transplant.²⁶

The urgency of early diagnosis becomes clear in this context. The sooner HRS-AKI is recognized and treatment initiated, the better the chances of reversing the kidney injury before it progresses to a point where only transplant can help. Recent changes in the diagnostic criteria have been designed with this in mind, aiming to identify patients at an earlier stage of kidney decline rather than waiting for the full syndrome to declare itself.²⁷

Pediatric Considerations

HRS can also develop in children with cirrhosis, though it is far less common and less well studied. The basic pathophysiology is the same, and the treatment approach follows adult paradigms: vasoconstrictors (mainly terlipressin) combined with albumin. Pediatric dosing and monitoring differ, and the evidence base is largely extrapolated from adult trials and case series rather than dedicated pediatric randomized trials.²⁸ Children with cirrhosis severe enough to develop HRS are typically already on a transplant pathway, making early recognition and bridge therapy equally critical in this group.

The Cost Barrier

Human albumin is a blood-derived product, manufactured from donated plasma, and it is expensive. In resource-limited healthcare systems, cost is a genuine barrier to using albumin for the albumin challenge, for SBP prophylaxis, and especially for long-term outpatient infusions. A cost-effectiveness analysis from Indonesia, modeled as a representative resource-limited setting, found that adding albumin to terlipressin for HRS cost roughly 1,339 euros per quality-adjusted life year gained, a figure that falls well within standard willingness-to-pay thresholds and suggests albumin is cost-effective even in lower-income countries.²⁹

In Thailand, a similar analysis found that at the local willingness-to-pay threshold, supportive care alone was most likely to be considered cost-effective (69% probability), while norepinephrine plus albumin reached 20% and terlipressin plus albumin only 11%.³⁰ These divergent results illustrate that cost-effectiveness depends heavily on local drug prices, access to transplantation, and the threshold a healthcare system sets for what it is willing to spend per life year gained. In wealthier systems, albumin use is rarely questioned on economic grounds. In countries where a single vial can consume a significant portion of a patient’s hospital budget, the calculus is genuinely difficult, and the push toward crystalloid alternatives takes on practical weight beyond the academic debate.